Welcome to the China clinical trial web page of the Leukocyte Infusion Therapy (LIFT) for cancer treatment pioneered by Dr. Zheng Cui of Wake Forest University. The trial in China is primarily intended for patients in China. However, due to the high demand for new cancer therapies, even at experimental stages, overseas patients who meet the inclusion criteria and are willing to travel to China and participate in these new trials may be considered for the trial.
This site is intended to inform overseas patients about the trial and provide an option for them to enroll if they meet the inclusion criteria and are interested in participating.
While many of Dr. Cui’s preclinical and preliminary clinical studies have shown promising results and the FDA has approved a combined phase I-II clinical trial in the US which is currently in process, a lack of conventional funding has limited the access of many patients to the US trial. Due to the significantly lower cost of medical procedures in China, it is now possible to conduct the clinical trials for testing LIFT in China for a larger number of subjects.
The first clinical trial in China is taking place at the 304 Hospital (See more about the 304 Hospital) in Beijing and its lead investigator is Dr. Wenhua Xiao (See Resume). It will include twenty-six patients and you can read more about it in the Who Can Participate? section.
If after reading through the information, you feel that you or someone you know qualifies as an applicant and are willing to spend one month in China for the treatment, you are welcome to fill out an application form. We will send you more information about the trial and have a clinical representative contact you to determine if you qualify.
China is home to millions of cancer patients. Data from this trial will help to accelerate the efforts and determine whether the therapy is safe and effective.